2022 World Conference on Lung Cancer (ePosters)-EP08.02-033. Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study

EP08.02-033. Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study

Back to course

Pdf Summary

This study aimed to assess the efficacy and safety of anlotinib in elderly patients with advanced non-squamous non-small cell lung cancer (NSCLC) who had not received systemic chemotherapy. Anlotinib is a novel multi Tyrosine Kinase Inhibitor that targets various receptors involved in cancer growth. <br /><br />The trial included 49 patients, of which 34 were evaluable. The median age of the patients was 75, and the majority were female. Most patients had stage IV cancer and a negative EGFR mutation status. <br /><br />The primary endpoint of the study was progression-free survival (PFS), while overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety were secondary endpoints. <br /><br />At the data cut-off, the median PFS was 4.8 months, and the median OS was not reached. The ORR was 5.9%, and the DCR was 85.3%. The most common grade 1-2 adverse events reported were hypertension, hand and foot skin reaction, and fatigue. <br /><br />Anlotinib treatment was found to be feasible and safe in elderly patients with advanced non-squamous NSCLC who had not received systemic chemotherapy. The study is still ongoing and continues to recruit patients. <br /><br />In conclusion, this phase II study demonstrates that anlotinib shows promising efficacy and acceptable safety outcomes in elderly patients with advanced non-squamous NSCLC. Further research is needed to validate these findings and determine the optimal use of anlotinib in this patient population.

Asset Subtitle

da zhao

Meta Tag

Speaker da zhao

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

anlotinib

efficacy

safety

elderly patients

advanced non-squamous NSCLC

systemic chemotherapy

tyrosine kinase inhibitor

progression-free survival

overall survival

objective response rate